Hemin pharmacotherapy optimization in a patient with acute intermittent porphyria: A case report
- Autores: Isabel Caba Porras, María Rosa Cantudo Cuenca, Juan Francisco Marín Pozo, Almudena Alcalá Sanz, Ana Acuña Vega
- Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 4, 2014, págs. 300-302
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Objective: To describe a method of intravenous administration other than that established in the summary of product characteristics of hemin-arginate. Method: A patient with acute intermittent porphyria, presented serious adverse reactions: phlebitis, swelling, pain, cellulitis, associated with the peripheral infusion of hemin-arginate in sodium chloride 0.9%. Different possibilities were explored to infuse the mixture and improve the tolerability. A clinical monitoring of the new method of administration described has been carried out.
Results: We implemented a new protocol for the administration of hemin-arginate with 20% albumin in equimolar amounts with respect to the dose, resulting in a hemin stable preparation tolerable in peripheral veins. After the application of the protocol during 13 months, none of the described adverse events was reported in the patient.
Conclusions: The new method of administration has proved to be safer, with the same effectiveness. We consider that our protocol for hemin-albumin administration can be extended to all patients who are candidates for this therapy. Pharmaceutical care benefits the health patient
